The connection between tricarboxylic acid cycle enzyme mutations and pseudohypoxic signaling in pheochromocytoma and paraganglioma.
VHL/HIF axis
genetic mutations
metabolic reprogramming
paraganglioma
pheochromocytoma
pseudohypoxia
tricarboxylic acid cycle
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
08
08
2023
accepted:
25
09
2023
medline:
1
11
2023
pubmed:
23
10
2023
entrez:
23
10
2023
Statut:
epublish
Résumé
Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors originating from chromaffin cells, holding significant clinical importance due to their capacity for excessive catecholamine secretion and associated cardiovascular complications. Roughly 80% of cases are associated with genetic mutations. Based on the functionality of these mutated genes, PPGLs can be categorized into distinct molecular clusters: the pseudohypoxia signaling cluster (Cluster-1), the kinase signaling cluster (Cluster-2), and the WNT signaling cluster (Cluster-3). A pivotal factor in the pathogenesis of PPGLs is hypoxia-inducible factor-2α (HIF2α), which becomes upregulated even under normoxic conditions, activating downstream transcriptional processes associated with pseudohypoxia. This adaptation provides tumor cells with a growth advantage and enhances their ability to thrive in adverse microenvironments. Moreover, pseudohypoxia disrupts immune cell communication, leading to the development of an immunosuppressive tumor microenvironment. Within Cluster-1a, metabolic perturbations are particularly pronounced. Mutations in enzymes associated with the tricarboxylic acid (TCA) cycle, such as succinate dehydrogenase (SDHx), fumarate hydratase (FH), isocitrate dehydrogenase (IDH), and malate dehydrogenase type 2 (MDH2), result in the accumulation of critical oncogenic metabolic intermediates. Notable among these intermediates are succinate, fumarate, and 2-hydroxyglutarate (2-HG), which promote activation of the HIFs signaling pathway through various mechanisms, thus inducing pseudohypoxia and facilitating tumorigenesis. SDHx mutations are prevalent in PPGLs, disrupting mitochondrial function and causing succinate accumulation, which competitively inhibits α-ketoglutarate-dependent dioxygenases. Consequently, this leads to global hypermethylation, epigenetic changes, and activation of HIFs. In FH-deficient cells, fumarate accumulation leads to protein succination, impacting cell function. FH mutations also trigger metabolic reprogramming towards glycolysis and lactate synthesis. IDH1/2 mutations generate D-2HG, inhibiting α-ketoglutarate-dependent dioxygenases and stabilizing HIFs. Similarly, MDH2 mutations are associated with HIF stability and pseudohypoxic response. Understanding the intricate relationship between metabolic enzyme mutations in the TCA cycle and pseudohypoxic signaling is crucial for unraveling the pathogenesis of PPGLs and developing targeted therapies. This knowledge enhances our comprehension of the pivotal role of cellular metabolism in PPGLs and holds implications for potential therapeutic advancements.
Identifiants
pubmed: 37867526
doi: 10.3389/fendo.2023.1274239
pmc: PMC10585109
doi:
Substances chimiques
Ketoglutaric Acids
0
Succinates
0
Succinic Acid
AB6MNQ6J6L
Fumarates
0
Dioxygenases
EC 1.13.11.-
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1274239Informations de copyright
Copyright © 2023 Wang, Liu, Li, Zhang, Gao, Wang and Zhou.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Hum Mutat. 2007 Feb;28(2):143-9
pubmed: 17024664
Hypertens Res. 2020 Nov;43(11):1141-1151
pubmed: 32778780
Exp Cell Res. 2017 Jul 15;356(2):192-196
pubmed: 28284840
Nature. 2012 Feb 15;483(7390):484-8
pubmed: 22343896
Nature. 2009 Dec 10;462(7274):739-44
pubmed: 19935646
J Intern Med. 2019 Feb;285(2):187-204
pubmed: 30536464
Horm Cancer. 2015 Dec;6(5-6):191-205
pubmed: 26138106
Curr Treat Options Oncol. 2020 Aug 29;21(11):85
pubmed: 32862332
J Biol Chem. 2002 Aug 23;277(34):30409-12
pubmed: 12087111
Nat Cell Biol. 2015 Oct;17(10):1317-26
pubmed: 26302408
Cancers (Basel). 2019 May 16;11(5):
pubmed: 31100940
J Med Chem. 2014 Nov 26;57(22):9522-38
pubmed: 25356789
Histopathology. 2018 Jan;72(1):106-116
pubmed: 29239034
Mol Cell. 2020 Jan 16;77(2):213-227.e5
pubmed: 31735641
J Clin Invest. 2022 Sep 15;132(18):
pubmed: 36106637
J Pathol. 2011 Sep;225(1):4-11
pubmed: 21630274
J Hypertens. 2020 Aug;38(8):1443-1456
pubmed: 32412940
J Surg Oncol. 2012 Oct 1;106(5):580-5
pubmed: 22648936
Cancer Cell. 2005 Jan;7(1):77-85
pubmed: 15652751
Lancet. 2003 Jun 14;361(9374):2059-67
pubmed: 12814730
Front Endocrinol (Lausanne). 2018 Nov 27;9:515
pubmed: 30538672
Exp Mol Med. 2013 Oct 04;45:e45
pubmed: 24091747
J Mol Med (Berl). 2013 Apr;91(4):507-12
pubmed: 23090011
Endocr Rev. 2023 Mar 4;44(2):312-322
pubmed: 36301191
Ann N Y Acad Sci. 2006 Aug;1073:104-11
pubmed: 17102077
Endocr Rev. 2014 Oct;35(5):795-819
pubmed: 25033281
Endocr Pract. 2018 Jan;24(1):78-90
pubmed: 29144820
Best Pract Res Clin Endocrinol Metab. 2010 Jun;24(3):415-24
pubmed: 20833333
Cancers (Basel). 2022 Jan 25;14(3):
pubmed: 35158861
Cell Commun Signal. 2016 Jan 12;14:3
pubmed: 26759054
Endocr Relat Cancer. 2023 May 11;30(6):
pubmed: 36897220
Lancet Diabetes Endocrinol. 2023 May;11(5):345-361
pubmed: 37011647
Mol Cell. 2008 May 23;30(4):393-402
pubmed: 18498744
Front Endocrinol (Lausanne). 2023 Jan 25;13:1070074
pubmed: 36760809
Nat Rev Cancer. 2011 Dec 15;12(1):9-22
pubmed: 22169972
Cancer Cell. 2010 Mar 16;17(3):225-34
pubmed: 20171147
J Natl Cancer Inst. 2015 Mar 11;107(5):
pubmed: 25766404
Oncogene. 2021 May;40(19):3351-3363
pubmed: 33864000
J Natl Cancer Inst. 2013 Sep 4;105(17):1270-83
pubmed: 23940289
Front Endocrinol (Lausanne). 2023 Mar 22;14:1137456
pubmed: 37033265
N Engl J Med. 2008 Dec 18;359(25):2685-92
pubmed: 19092153
Semin Cancer Biol. 2013 Feb;23(1):18-25
pubmed: 22705278
Endocr Pathol. 2022 Mar;33(1):90-114
pubmed: 35285002
J Clin Endocrinol Metab. 2014 Oct;99(10):3903-11
pubmed: 25014000
Pediatr Blood Cancer. 2021 Jul;68(7):e28981
pubmed: 33682326
Clin Cancer Res. 2009 Oct 15;15(20):6378-85
pubmed: 19825962
PLoS One. 2016 Sep 09;11(9):e0162568
pubmed: 27611801
Epigenetics. 2013 Dec;8(12):1347-54
pubmed: 24149047
Biomed Pharmacother. 2017 May;89:805-811
pubmed: 28273642
Genet Med. 2018 Dec;20(12):1652-1662
pubmed: 30008476
Endocr Relat Cancer. 2015 Aug;22(4):T83-90
pubmed: 26113605
Cell Cycle. 2014;13(5):699-709
pubmed: 24526120
Biochim Biophys Acta. 2012 Sep;1823(9):1468-83
pubmed: 22610083
Front Endocrinol (Lausanne). 2020 Nov 24;11:586857
pubmed: 33329393
Genet Med. 2018 Oct;20(10):1266-1273
pubmed: 29595810
Mol Cancer Ther. 2009 Mar;8(3):626-35
pubmed: 19276158
Oncoimmunology. 2018 Mar 26;7(7):e1445454
pubmed: 29900057
J Mol Med (Berl). 2011 Mar;89(3):213-20
pubmed: 21301796
Oncogene. 2006 Aug 7;25(34):4675-82
pubmed: 16892081
Clin Cancer Res. 2020 Jul 15;26(14):3868-3880
pubmed: 32152203
Anal Biochem. 2018 Jul 1;552:50-59
pubmed: 28711444
Hum Mol Genet. 2011 Oct 15;20(20):3974-85
pubmed: 21784903
J Clin Endocrinol Metab. 2007 Oct;92(10):3822-8
pubmed: 17652212
Cancers (Basel). 2021 Feb 21;13(4):
pubmed: 33670082
J Mol Endocrinol. 2023 Jan 24;70(3):
pubmed: 36520714
Cancer Med. 2023 Jul;12(13):13942-13957
pubmed: 37145019
Front Endocrinol (Lausanne). 2021 Mar 12;12:589451
pubmed: 33776908
Nat Commun. 2015 Nov 02;6:8784
pubmed: 26522426
Crit Rev Oncol Hematol. 2016 Apr;100:190-208
pubmed: 26839173
Front Endocrinol (Lausanne). 2020 Oct 27;11:587769
pubmed: 33193100
J Biomed Sci. 2022 Nov 7;29(1):93
pubmed: 36344992
Mol Cell Biol. 2017 May 16;37(11):
pubmed: 28289076
Sci Immunol. 2022 Apr 29;7(70):eabm8161
pubmed: 35486677
Cancer Cell. 2005 Aug;8(2):143-53
pubmed: 16098467
J Clin Endocrinol Metab. 2014 Aug;99(8):E1482-6
pubmed: 24758179
Int J Mol Sci. 2022 Nov 17;23(22):
pubmed: 36430733
Front Endocrinol (Lausanne). 2023 Jan 09;13:1103075
pubmed: 36699028
Front Oncol. 2019 Jun 12;9:506
pubmed: 31263678
FASEB J. 2019 Dec;33(12):13398-13411
pubmed: 31530011
Elife. 2022 Feb 21;11:
pubmed: 35188460
Nat Rev Endocrinol. 2015 Feb;11(2):101-11
pubmed: 25385035
J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42
pubmed: 24893135
Front Oncol. 2019 Feb 22;9:53
pubmed: 30854332
JAMA. 2010 Dec 15;304(23):2611-9
pubmed: 21156949
Interface Focus. 2017 Apr 6;7(2):20160100
pubmed: 28382199
Curr Oncol Rep. 2022 Jan;24(1):89-98
pubmed: 35061191
Best Pract Res Clin Endocrinol Metab. 2020 Mar;34(2):101416
pubmed: 32295730
Science. 2009 Apr 10;324(5924):261-5
pubmed: 19359588
Trends Cancer. 2018 Jan;4(1):6-9
pubmed: 29413423
Cell Rep. 2021 Jun 15;35(11):109246
pubmed: 34133934
J Clin Endocrinol Metab. 2021 Apr 23;106(5):e2251-e2261
pubmed: 33479747
Cell Metab. 2006 Mar;3(3):177-85
pubmed: 16517405
J Natl Cancer Inst. 2022 Jan 11;114(1):130-138
pubmed: 34415331
Nature. 2011 Aug 17;477(7363):225-8
pubmed: 21849978
Front Endocrinol (Lausanne). 2020 Dec 11;11:574662
pubmed: 33362715
Science. 2022 Sep 30;377(6614):1519-1529
pubmed: 36173860
Hum Mol Genet. 2005 Aug 1;14(15):2231-9
pubmed: 15987702
Endocr Relat Cancer. 2020 Dec;27(12):R451-R463
pubmed: 33112834
Arch Biochem Biophys. 2006 Jun 1;450(1):1-8
pubmed: 16624247
J Endocr Soc. 2022 Jul 03;6(9):bvac105
pubmed: 35919261
Nat Rev Clin Oncol. 2021 Dec;18(12):751-772
pubmed: 34326502
J Clin Endocrinol Metab. 2019 Jun 1;104(6):2367-2374
pubmed: 30715419
Neuro Oncol. 2016 Jan;18(1):16-26
pubmed: 26188014
J Pathol. 2023 Jan;259(1):103-114
pubmed: 36314599
Endocr Rev. 2022 Mar 9;43(2):199-239
pubmed: 34147030
Blood. 2014 Dec 4;124(24):3597-607
pubmed: 25267197
J Clin Endocrinol Metab. 2010 Mar;95(3):1274-8
pubmed: 19915015
Clin Cancer Res. 2007 Aug 15;13(16):4667-71
pubmed: 17699843
Biochem Soc Trans. 2016 Aug 15;44(4):1111-6
pubmed: 27528759
Cell. 2017 Oct 5;171(2):358-371.e9
pubmed: 28985563
J Clin Endocrinol Metab. 2022 Nov 23;107(11):2963-2972
pubmed: 35973976
Nature. 2006 May 25;441(7092):437-43
pubmed: 16724055